Calc Function

    • Calcs that help predict probability of a diseaseDiagnosis
    • Subcategory of 'Diagnosis' designed to be very sensitiveRule Out
    • Disease is diagnosed: prognosticate to guide treatmentPrognosis
    • Numerical inputs and outputsFormula
    • Med treatment and moreTreatment
    • Suggested protocolsAlgorithm

    Disease

    Select...

    Specialty

    Select...

    Chief Complaint

    Select...

    Organ System

    Select...

    Patent Pending

    Sokal Index for CML

    Predicts survival of CML based on clinical and lab information.
    Favorite
    When to Use
    Pearls/Pitfalls

    Stratifying patients enrolled in clinical trials.

    The Sokal score was created in 1984, before tyrosine kinase inhibitors became first-line in treatment of CML. Survival rates have improved since then.

    years
    in
    ×10³/µL
    %

    Result:

    Please fill out required fields.

    Next Steps
    Evidence
    Creator Insights

    Formula

    Sokal Score = exp (0.0116 x (age [years] – 43.4)) + (0.0345 x (spleen size [cm] – 7.51) + (0.188 x ((platelets [109/L]/700)2 – 0.563)) + (0.0887 x (blasts [%] – 2.10))

    Facts & Figures

    Based on analysis of survival of 813 patients diagnosed with chronic phase CML between 1962 and 1981. Most patients were treated with single-agent chemotherapy, typically busulfan.

    Score interpretation:

    Risk GroupSokal Score2 year SurvivalMedian Survival time
    Low<0.890%5 years
    Intermediate0.8 - 1.265-90%2.5-5 years
    High>1.265%2.5 years
    Dr. Joseph E. Sokal

    About the Creator

    Joseph E. Sokal, MD, (d. 1988) was a researcher in cancer treatment and a scholar in residence at Duke University. Previously, he was chief cancer research clinician at Roswell Park Memorial Institute in Buffalo and an assistant professor at Yale University.

    To view Dr. Joseph E. Sokal's publications, visit PubMed